Pancreatic Cancer Research

ResearcherZhongda Hospital Southeast UniversityActive in the last 2 years

Fangfang Hu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5130626151. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 3

  1. CAFs-derived LAM332 promotes CTCs formation and survival via ITGA3 and contributes to the metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-026-08642-z↗
  2. A five-gene prognosis model based on lysine β-hydroxybutyrylation site genes to predict the survival and therapy response in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.heliyon.2024.e34284↗
  3. Diabetes mellitus stimulates pancreatic cancer growth and epithelial-mesenchymal transition-mediated metastasis via a p38 MAPK pathway. Co-author DOI 10.18632/oncotarget.9533↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiahua Zhou · 2 shared papers, 2024–2026 · strength 0.56
  2. Zhibin Bai · 1 shared paper, 2024 · strength 0.28
  3. Pengcheng Zhou · 1 shared paper, 2026 · strength 0.28
  4. Haodong Tang · 1 shared paper, 2026 · strength 0.28
  5. Zeqian Yu · 1 shared paper, 2016 · strength 0.06
  6. Yang Yang · 1 shared paper, 2016 · strength 0.06
  7. Lishan Wang · 1 shared paper, 2016 · strength 0.06
  8. Jiahua Zhou · 1 shared paper, 2016 · strength 0.06
  9. Yong-Hui Wang · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.